These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38784388)

  • 1. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
    Hu Q; Li F; Yang K
    PeerJ; 2024; 12():e17391. PubMed ID: 38784388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
    Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
    Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
    Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
    Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
    Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.
    Swain M; Kannan S; Srinivasan S; Agarwal JP; Gupta T
    Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):786-795. PubMed ID: 35387752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
    Yoshida EJ; Luu M; Mallen-St Clair J; Mita AC; Scher KS; Lu DJ; Nguyen AT; Shiao SL; Ho AS; Zumsteg ZS
    Cancer; 2020 Jan; 126(1):58-66. PubMed ID: 31536144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
    J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
    Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
    Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
    Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma.
    Rasmussen JH; Grønhøj C; Håkansson K; Friborg J; Andersen E; Lelkaitis G; Klussmann JP; Wittekindt C; Wagner S; Vogelius IR; von Buchwald C
    Ann Oncol; 2019 Apr; 30(4):629-636. PubMed ID: 30657857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
    Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
    Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the 8
    van Gysen K; Stevens M; Guo L; Jayamanne D; Veivers D; Wignall A; Pang L; Guminski A; Lee A; Hruby G; Macleod P; Taylor A; Eade T
    BMC Cancer; 2019 Jul; 19(1):674. PubMed ID: 31288767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
    Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
    Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
    Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes in Human Papillomavirus-Associated Nonoropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-analysis.
    Sahovaler A; Kim MH; Mendez A; Palma D; Fung K; Yoo J; Nichols AC; MacNeil SD
    JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1158-1166. PubMed ID: 33057610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Therapy Alone for Human Papillomavirus-Related Squamous Cell Carcinoma of the Oropharynx: A Single-Arm, Phase 2 Study.
    Takemoto N; Seo Y; Nakahara S; Yoshioka Y; Teshima T; Fujii T; Isohashi F; Otani K; Yoshii T; Takenaka Y; Suzuki M; Fukusumi T; Hanamoto A; Yasui T; Michiba T; Yamamoto Y; Shimamoto S; Tanaka H; Tatsumi M; Ogawa K; Inohara H
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):403-411. PubMed ID: 33373656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.